Neovascular age-related macular degeneration: individualizing therapy in the era of anti-angiogenic treatments.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 23642783.
- Also identified by DOI 10.1016/j.ophtha.2013.01.059.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The treatment of neovascular age-related macular degeneration (AMD) had been revolutionized by the use of anti-vascular endothelial growth factor (VEGF) drugs: bevacizumab and ranibizumab. With the introduction of a third anti-VEGF drug, aflibercept, ophthalmologists have several options to choose from, as well as various treatment regimens they can follow. In this Interview, Jeffrey S. Heier, MD, of Ophthalmic Consultants of Boston, Massachusetts, discusses his approaches to managing the treatment of patients with AMD and providing them with individualized care.
Medical subject headings
- Angiogenesis Inhibitors
- Macular Degeneration
- Precision Medicine
- Vascular Endothelial Growth Factors